Shopping Cart is Empty..

$ 0

Recombinant Coagulation Factors Market by Product Type (Recombinant Factor VIII, Recombinant Factor IX, and Von Willebrand Factor), by Hemophilia Type (Hemophilia A and Hemophilia B), and by End User (Hospitals, Clinics, and Research Organizations) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI 173265	Pages: NA	Formats*:
Nov 2017 \| 88 Views	Charts: NA	Tables: NA	Author(s): NA

Recombinant coagulation factors are plasma derived counterparts used to treat infection from viruses such as hepatitis C and the human immunodeficiency virus. In addition, recombinant coagulation factors have low risk for transmission of infectious agents.

Increase in number of hemophilia patients and rise in number of R&D on coagulation factors drive the market. However, high cost associated with hemophilia treatment and availability of alternative recombinant coagulation factors impede the market growth. Moreover, the expansion of the business in developing economies such as China, India, and Brazil create more lucrative opportunities for the market.

The global recombinant coagulation factors market is segmented based on product type, hemophilia type, end user, and geography. Based on product type, the market is classified into recombinant factor VIII, recombinant factor IX, and Von Willebrand factor. Based on hemophilia type, the market is divided into hemophilia A and hemophilia B. Based on end user, it is categorized into hospitals, clinics, and research organizations. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Baxter International Inc., Bayer AG, Biogen Idec, CSL Ltd., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, Octapharma AG, and Pfizer Inc. are also provided in this report.

Key Benefits

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global recombinant coagulation factors market.
In-depth analysis is conducted by constructing market estimations for the key market segments between 2016 and 2023.
This study evaluating competitive landscape and value chain is taken into account to help understand the competitive environment across the geographies.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
This report provides the quantitative analysis of the current market and estimations through 2016-2023, which assists in identifying the prevailing market opportunities
Comprehensive analysis of all regions are provided that determines the prevailing opportunities in these geographies.

Recombinant Coagulation Factors Market Key Segments:

By Product Type

Recombinant Factor VIII
Recombinant Factor IX
Von Willebrand Factor

By Hemophilia Type

Hemophilia A
Hemophilia B

By End User

Hospitals
Clinics
Research Organizations

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- U.K
- France
- Germany
- Spain
- Rest of Europe
Asia-Pacific
- China
- India
- Australia
- Japan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

Enquiry About Report

Please input above shown text into input box
or click refresh

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

License Type

Data Pack

Single User PDF

Five User Online/PDF

Enterprise Online/PDF

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

One Print only

Up to Five Copies

Unlimited within company / enterprise

Delivery Formats

ADDED BENIFITS

20% Free customization (Pre-sale)

16 Analyst hour support (Post Sale)

40 Analyst hour support (Post Sale)

160 hours of mini-consult

Free quarterly industry update

Free report on update (within 180 days)

MULTIPLE PURCHASE

Complimentary report with 2 reports

Complimentary report with 3 reports

Subscription Model

Have questions ?
Speak with analyst

Did you miss anything?
To add more

* Taxes/Fees, If applicable, will be
added at the checkout. All prices in USD.

Need More Information

+1-503-894-6022

help@alliedmarketresearch.com

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to eliminate redundant information to provide valued information and save time of the reader

Get fresh content delivered

Get insights on topics that matter to your business. Stay updated on the areas that interest you.

Report Title: Recombinant Coagulation Factors Market by Product Type (Recombinant Factor VIII, Recombinant Factor IX, and Von Willebrand Factor), by Hemophilia Type (Hemophilia A and Hemophilia B), and by End User (Hospitals, Clinics, and Research Organizations) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Select Chapters

Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 Chapter 8

Full Name: *:

Company Name: *:

Job Role: *:

Email: *:

Country: *:

Contact Number: *:

How can we help? *:

Security Code: *:

STAY WITH US

WE ACCEPT

* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Chapter: 1 INTRODUCTION 1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models
Chapter: 2 EXECUTIVE SUMMARY 2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW 3.1. MARKET DEFINITION AND SCOPE 3.2. KEY FINDINGS 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016 3.4. PORTER’S FIVE FORCES ANALYSIS 3.5. MARKET DYNAMICS 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities
Chapter: 4 RECOMBINANT COAGULATION FACTORS MARKET, BY PRODUCT TYPE 4.1. OVERVIEW 4.1.1. Key market trends 4.1.2. Growth factors and opportunities 4.1.3. Market size and forecast 4.2. RECOMBINANT FACTOR VIII 4.2.1. Key market trends 4.2.2. Growth factors and opportunities 4.2.3. Market size and forecast 4.3. RECOMBINANT FACTOR IX 4.3.1. Key market trends 4.3.2. Growth factors and opportunities 4.3.3. Market size and forecast 4.4. VON WILLEBRAND FACTOR 4.4.1. Key market trends 4.4.2. Growth factors and opportunities 4.4.3. Market size and forecast
Chapter: 5 RECOMBINANT COAGULATION FACTORS MARKET, BY HEMOPHILIA TYPE 5.1. OVERVIEW 5.1.1. Market size and forecast 5.2. HEMOPHILIA A 5.2.1. Market size and forecast 5.3. HEMOPHILIA B 5.3.1. Market size and forecast
Chapter: 6 RECOMBINANT COAGULATION FACTORS MARKET, BY END USER 6.1. OVERVIEW 6.1.1. Market size and forecast 6.2. HOSPITALS 6.2.1. Market size and forecast 6.3. CLINICS 6.3.1. Market size and forecast 6.4. RESEARCH ORGANIZATIONS 6.4.1. Market size and forecast
Chapter: 7 RECOMBINANT COAGULATION FACTORSMARKET, BY REGION 7.1. OVERVIEW 7.2. NORTH AMERICA 7.2.1. Key market trends 7.2.2. Key growth factors and opportunities 7.2.3. Market size and forecast 7.2.3.1. U.S. market size and forecast 7.2.3.2. Canada market size and forecast 7.2.3.3. Mexico market size and forecast 7.2.4. North America Recombinant Coagulation Factors Market by Product Type 7.2.5. North America Recombinant Coagulation Factors Market by Hemophilia Type 7.2.6. North America Recombinant Coagulation Factors Market by End User 7.3. EUROPE 7.3.1. Key market trends 7.3.2. Key growth factors and opportunities 7.3.3. Market size and forecast 7.3.3.1. Germany market size and forecast 7.3.3.2. France market size and forecast 7.3.3.3. UK market size and forecast 7.3.3.4. Spain market size and forecast 7.3.3.5. Rest of Europe market size and forecast 7.3.4. Europe Recombinant Coagulation Factors Market By Product Type 7.3.5. Europe Recombinant Coagulation Factors Market By Hemophilia Type 7.3.6. Europe Recombinant Coagulation Factors Market By End User 7.4. ASIA-PACIFIC 7.4.1. Key market trends 7.4.2. Key growth factors and opportunities 7.4.3. Market size and forecast 7.4.3.1. Japan market size and forecast 7.4.3.2. China market size and forecast 7.4.3.3. Australia market size and forecast 7.4.3.4. India market size and forecast 7.4.3.5. Rest of Asia-Pacific market size and forecast 7.4.4. Asia Pacific Recombinant Coagulation FactorsMarket By Product Type 7.4.5. Asia Pacific Recombinant Coagulation FactorsMarket By Hemophilia Type 7.4.6. Asia Pacific Recombinant Coagulation FactorsMarket By End User 7.5. LAMEA 7.5.1. Key market trends 7.5.2. Key growth factors and opportunities 7.5.3. Market size and forecast 7.5.3.1. Brazil market size and forecast 7.5.3.2. Turkey market size and forecast 7.5.3.3. Saudi Arabia market size and forecast 7.5.3.4. South Africa market size and forecast 7.5.3.5. Rest of LAMEA market size and forecast 7.5.4. LAMEA Recombinant Coagulation FactorsMarket By Product Type 7.5.5. LAMEA Recombinant Coagulation FactorsMarket By Hemophilia Type 7.5.6. LAMEA Recombinant Coagulation FactorsMarket By End User
Chapter: 8 COMPANY PROFILES 8.1. BAXTER INTERNATIONAL INC. 8.1.1. Operating business segments 8.1.2. Business performance 8.1.3. Key strategic moves and developments 8.2. BAYER AG 8.2.1. Operating business segments 8.2.2. Business performance 8.2.3. Key strategic moves and developments 8.3. BIOGEN IDEC 8.3.1. Operating business segments 8.3.2. Business performance 8.3.3. Key strategic moves and developments 8.4. CSL LTD. 8.4.1. Operating business segments 8.4.2. Business performance 8.4.3. Key strategic moves and developments 8.5. GRIFOLS INTERNATIONAL SA 8.5.1. Operating business segments 8.5.2. Business performance 8.5.3. Key strategic moves and developments 8.6. KEDRION S.P.A. 8.6.1. Operating business segments 8.6.2. Business performance 8.6.3. Key strategic moves and developments 8.7. NOVO NORDISK A/S 8.7.1. Operating business segments 8.7.2. Business performance 8.7.3. Key strategic moves and developments 8.8. OCTAPHARMA AG 8.8.1. Operating business segments 8.8.2. Business performance 8.8.3. Key strategic moves and developments 8.9. PFIZER INC. 8.9.1. Operating business segments 8.9.2. Business performance 8.9.3. Key strategic moves and developments

Purchase Options